Literature DB >> 8949764

European results in neutron therapy of malignant salivary gland tumors.

A Krüll1, R Schwarz, R Engenhart, P Huber, A Lessel, H Koppe, A Favre, N Breteau, T Auberger.   

Abstract

In Europe to date, 501 patients with salivary gland tumors have been treated with neutrons alone or with combined modalities. The most common histological types are adenoid cystic carcinomas, mucoepidermoid carcinomas and malignant mixed tumors. The results of conventional radiotherapy are suboptimal in inoperable or incompletely resected salivary gland tumors and in recurrent disease. The pooled data of some international series for low linear energy transfer radiation show a local control of 28%. Especially in advanced tumors neutron therapy can improve local control and should be the treatment of choice. The clinical data from different therapy centers in Europe show local control of 67% in gross disease.

Entities:  

Mesh:

Year:  1996        PMID: 8949764     DOI: 10.1016/0924-4212(96)84897-3

Source DB:  PubMed          Journal:  Bull Cancer Radiother        ISSN: 0924-4212


  4 in total

1.  [CT densitometry for the grading of subcutaneous fibrosis after the photon-neutron therapy of malignant salivary gland tumors].

Authors:  H T Eich; P D Eich; M Stuschke; R D Müller; H Sack
Journal:  Strahlenther Onkol       Date:  1999-03       Impact factor: 3.621

Review 2.  [Salivary gland carcinomas Part II. Diagnosis and therapy].

Authors:  S Lang; N Rotter; A Lorenzen; S Ihrler; R Eckel; D Hölzel; G Rasp; B Wollenberg; K Sommer
Journal:  HNO       Date:  2005-10       Impact factor: 1.284

3.  Parotid carcinoma: Current diagnostic workup and treatment.

Authors:  Vincent L M Vander Poorten; Francis Marchal; Sandra Nuyts; Paul M J Clement
Journal:  Indian J Surg Oncol       Date:  2010-11-21

4.  Paving the Road for Modern Particle Therapy - What Can We Learn from the Experience Gained with Fast Neutron Therapy in Munich?

Authors:  Hanno M Specht; Teresa Neff; Waltraud Reuschel; Franz M Wagner; Severin Kampfer; Jan J Wilkens; Winfried Petry; Stephanie E Combs
Journal:  Front Oncol       Date:  2015-11-27       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.